Tadalafil 2.5 mg + Tadalafil 5 mg + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Benign Prostatic Hyperplasia
Conditions
Benign Prostatic Hyperplasia
Trial Timeline
Nov 1, 2008 → Apr 1, 2010
NCT ID
NCT00783094About Tadalafil 2.5 mg + Tadalafil 5 mg + Placebo
Tadalafil 2.5 mg + Tadalafil 5 mg + Placebo is a phase 2 stage product being developed by Eli Lilly for Benign Prostatic Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT00783094. Target conditions include Benign Prostatic Hyperplasia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00783094 | Phase 2 | Completed |
Competing Products
20 competing products in Benign Prostatic Hyperplasia